RDFA
HRMY icon

Ritter Daniher Financial Advisory’s Harmony Biosciences HRMY Stock Holding History

Ritter Daniher Financial Advisory’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146 Buy
4
+1
+33% +$32 ﹤0.01% 592
2026
Q1 		$85 Buy
+3
New +$98 ﹤0.01% 580

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ritter Daniher Financial Advisory's HRMY Position: Q2 2026 in Review

Ritter Daniher Financial Advisory increased its Harmony Biosciences (HRMY) stake by 33% in Q2 2026, buying an estimated $32 and bringing the position to 4 shares worth $146. The position accounts for ﹤0.01% of the portfolio, ranked #592.

Ritter Daniher Financial Advisory first reported a position in HRMY in Q1 2026 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Ritter Daniher Financial Advisory held 4 shares of Harmony Biosciences worth $146 as of Q2 2026.
  • Ritter Daniher Financial Advisory bought 1 Harmony Biosciences share in Q2 2026, an estimated $32.
  • Harmony Biosciences made up ﹤0.01% of Ritter Daniher Financial Advisory's portfolio in Q2 2026, its #592 holding.
  • Ritter Daniher Financial Advisory first reported a position in Harmony Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Ritter Daniher Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.